General Information

Mouse: CB576J

Expression of the  human C-terminal-truncated (1-119) wild type alpha-synuclein protein under the control of the endogenous ROSA26 promoter in a Cre recombinase-dependent manner. Breeding with TH-Cre transgenic mice allows the selective expression of the transgene in dopaminergic neurons.

Endogenous mouse alpha synuclein: Yes.

Corresponding human genotype: Truncated form of alpha-synuclein are detected in brain tissue from post mortem PD brain and are enriched in Lewy bodies

Transgene insertion: ROSA26 locus

References: Daher 2009

Transgene expression

  • 10 months: Transgene expression is observed  in TH positive neurons and/or terminals, including olfactory bulb, striatum, cerebral cortex and ventral midbrain. Expression of the truncated human alpha-synuclein(1-119) protein is less than 10% of that of the endogenous mouse protein.

Neurodegeneration

  • 10-12 months: No loss of TH-positive neurons is observed.
    No change in survival is observed up to 18 months of age.

Dopamine Homeostasis

  • 12-13 months: A marked reduction of dopamine levels and its metabolites (homovanillic acid and DOPAC) are observed only in the striatum (normal levels are detected in the olfactory bulb as well as in the cerebral and prefrontal cortex). The reduction of dopamine seems to correlate with expression levels of the transgene. Normal striatal levels of 5-HT are observed.
  • 10-11 months: Increased levels of norepinephrine are observed in the striatum

Inclusions

  • Not reported

Motor Behaviours

  • Not reported

Response to L-DOPA treatment

  • Not reported

Non motor Behaviours

  • Not reported

Electrophysiology

  • Not reported

Neuroinflammation

  • Not reported

Leave a Reply

Your email address will not be published.